DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Clinical trials for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS trials appear
Sign up with your email to follow new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody drug firsekibart tested for scleroderma skin thickening
Disease control Not yet recruitingThis early-stage trial will test a new drug called firsekibart in 30 people with systemic sclerosis (scleroderma), a disease that causes skin thickening and organ damage. Firsekibart is an antibody that blocks a protein involved in inflammation. The study will measure changes in …
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: NA • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Could blocking TL1A stop skin scarring in scleroderma? early lab study hints at possibility
Knowledge-focused Not yet recruitingThis study will test if blocking a protein called TL1A can reverse skin scarring in systemic sclerosis, a rare autoimmune disease. Researchers will take blood and skin samples from 10 patients with early diffuse scleroderma and 10 healthy people. They will treat the samples in th…
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Sponsor: Fondazione Policlinico Universitario Campus Bio-Medico • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC